Skip to main content
博迅生物 logo

博迅生物 — Investor Relations & Filings

Ticker · 920504 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 301 across all filing types
Latest filing 2024-03-14 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920504

About 博迅生物

http://www.boxun.com.cn/

Boxun Medical Biological Instrument Corp. specializes in the development and manufacture of laboratory equipment and medical instruments. The company's core product line includes high-pressure steam sterilizers, constant temperature incubators, CO2 incubators, drying ovens, and environmental test chambers. These instruments are designed for applications in life sciences, healthcare, pharmaceutical research, and environmental monitoring. Boxun focuses on delivering precise thermal control and reliable sterilization solutions, ensuring compliance with international quality standards. Its equipment is utilized in scientific research, clinical diagnostics, and industrial quality control to maintain sterile environments and stable experimental conditions. The company emphasizes technical innovation and product durability to support the requirements of modern laboratory facilities.

Recent filings

Filing Released Lang Actions
关于使用闲置自有资金购买理财产品的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shanghai Boxun Medical Biological Instruments Co., Ltd. regarding the use of idle funds to purchase financial products. It details the purpose, amount, types of products, decision-making process, risk analysis, and impact on the company. The document is relatively short (1881 characters) and does not contain any financial statements or detailed financial data. It is an update on a financing-related activity but not a comprehensive financial report or earnings release. It is not a report publication announcement since it contains substantive information about the financing decision. The content fits best under Capital/Financing Update (CAP) as it relates to the company's use of capital for investment in financial products.
2024-03-14 Chinese
上海博迅医疗生物仪器股份有限公司控股股东及其他关联方资金占用情况的专项说明
Regulatory Filings
2024-03-14 Chinese
募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "专项报告" (special report) on the storage and actual use of raised funds (募集资金存放与实际使用情况的专项报告). It details the amount of funds raised through a public offering, the timing of fund receipt, usage amounts, balances, and management of the raised funds. It also includes auditor verification reports and sponsor institution opinions on the use of the raised funds. The document references regulatory approvals and compliance with securities laws and stock exchange rules. The content focuses exclusively on the management and use of capital raised from a share issuance, including cash management and replacement of pre-invested funds. This type of report is a specialized disclosure related to capital raising activities and fund usage, which fits the category of Capital/Financing Update (CAP). The document is substantive (6721 characters) and contains detailed financial and operational data about the capital raised and its use, not merely an announcement or certification. Therefore, it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA). It is not an Annual Report, Interim Report, or Earnings Release, nor does it relate to board changes, voting results, or legal proceedings. Hence, the best fitting classification is CAP (Capital/Financing Update).
2024-03-14 Chinese
国金证券股份有限公司关于上海博迅医疗生物仪器股份有限预计2024年日常性关联交易的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a specialized verification opinion from a sponsoring institution (国金证券股份有限公司) regarding the expected 2024 routine related-party transactions of Shanghai Boxun Medical Biological Instruments Co., Ltd. It includes detailed descriptions of the related-party transactions, pricing basis, fairness, approval procedures by the board, supervisory board, and independent directors, and the sponsor's verification opinion. The document is not a full financial report, earnings release, or regulatory filing but a specific audit or verification report related to compliance and fairness of related-party transactions. It does not announce voting results, changes in management, or capital structure. The document length is about 2155 characters, which is relatively short but contains substantive content about the audit of related-party transactions. Therefore, it fits best under Audit Report / Information (AR). FY 2024
2024-03-14 Chinese
董事会审计委员会2023年度履职情况报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from the Board Audit Committee of Shanghai Boxun Medical Biological Instruments Co., Ltd. for the year 2023. It describes the committee's activities, meetings, oversight of financial reports, audit supervision, internal audit guidance, and overall evaluation of their duties during the year. The content focuses on audit committee responsibilities and their review of financial reports and internal controls, which aligns with an Audit Report / Information filing. The document is not an announcement or a brief notice but a substantive report on audit committee activities and opinions, thus it is not a Regulatory Filing or Report Publication Announcement. The length and detail confirm it is a standalone audit-related report rather than a full Annual Report or Interim Report. Therefore, the appropriate classification is Audit Report / Information (AR). FY 2023
2024-03-14 Chinese
2023年年度报告
Annual Report Classification · 100% confidence The document is titled as an "年度报告" which translates to "Annual Report" and covers the fiscal year 2023. It includes detailed sections such as company overview, financial data and indicators, management discussion and analysis, major events, shareholder information, financing and profit distribution, board and management details, industry information, corporate governance, internal controls, and financial accounting reports. The presence of audited financial statements and a standard unqualified audit opinion from a CPA firm further confirms this is a comprehensive annual report. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or summary. Therefore, it fits the definition of an Annual Report (10-K). FY 2023
2024-03-14 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.